Prescient (ASX:PTX) ends last quarter on firm financial footing and key clinical developments – Kalkine Media
Prescient (ASX:PTX) highlights that its latest quarter achievements have strengthened its mark as an evolving...
Prescient (ASX:PTX) highlights that its latest quarter achievements have strengthened its mark as an evolving...
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is guided by its mission to develop novel, personalised therapies for...
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) is focused on developing its innovative pipeline in personalised medicine to...
Stockhead’s Year in Review video series is a yearly wrap up address from company leaders...
Since the last trial update, a patient with relapsed peripheral T cell lymphoma reported a...
Prescient Therapeutics (ASX:PTX), an Australian biotech player developing personalised medicine therapies for cancer, has published...
It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings...
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX), has provided an upbeat update regarding the encouraging clinical...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.